James Lugg, MD
Location & Hours
Affiliate Organizations
Copyright and Privacy
The Urgent PC product is a minimally invasive, office-based, non-surgical PTNS device for the treatment of OAB in men and women suffering with symptoms of urinary urge incontinence, urgency and frequency. The drug therapy is a bladder anti-spasmodic drug, also referred to as an anticholinergic medication. Both products are FDA cleared and available for sale in the United States, and both products are used for the non-surgical treatment of OAB symptoms. Over 34 million Americans suffer from OAB symptoms dramatically impacting the quality of their lives. These symptoms include urinary accidents, sudden urges, and frequent visits to a bathroom. Physicians, patients and third party payers throughout the world are embracing the office-based therapy provided by the Urgent PC. The minimally invasive stimulation therapy is a cost and clinically effective, non-surgical, non-drug alternative treatment for an individual with an OAB. David B. Kaysen, President and CEO of Uroplasty said, “Patients suffering from OAB symptoms are seeking an effective treatment with minimal side effects. Coming off our just announced FDA clearance for the Urgent PC, as well as our announced national reimbursement coverage from Aetna and coverage by a number of Blue Cross and Blue Shield health plans, this study is expected to build upon the already significant clinical evidence base for Urgent PC by demonstrating its clinical and cost effectiveness as compared to the standard pharmaceutical therapy used today. The relationships we are developing with key physicians and medical institutions signing up for this study should immediately lay the groundwork for our United States launch of the Urgent PC
2301 House Street, Suite 500, Cheyenne, Wyoming 82001
(307) 635-4131
- info@cheyenneurological.com